Urovant Sciences Ltd. (Nasdaq: UROV) named Jim Robinson president and chief executive, replacing Keith Katkin and effective immediately.
Before joining the clinical stage urologic drug company, Robinson was president and chief operating officer at pharma firm incubator Paragon Biosciences in Chicago, as well as at drug maker Alkermes Plc (Nasdaq: ALKS) in Dublin; prior to that he was as president, Americas, for Tokyo-based Astellas Pharma Inc. (OTC: ALPMY).
Sumitomo Dainippon Pharma late last year bought a majority stake in Urovant as part of a $3 billion deal involving five healthcare firms under London-based holding company Roivant Sciences and its founder Vivek Ramaswamy.
Irvine-based Urovant traded recently at a $300 million market cap.
